Circulation Research, Vol 69, 959-964, Copyright © 1991 by American Heart Association

ARTICLES

In vivo demonstration of cardiac beta 2-adrenoreceptor sensitization by beta 1-antagonist treatment

JA Hall, MC Petch and MJ Brown
Clinical Pharmacology Unit, Addenbrooke's Hospital, Cambridge, UK.

Treatment with beta 1-selective antagonists causes selective sensitization of isolated strips of human atrial myocardium to the inotropic action of epinephrine and beta 2-agonists but not of norepinephrine. To determine whether beta 1-selective antagonist treatment alters the responsiveness of cardiac beta 2-adrenoreceptors in vivo, we measured the positive chronotropic responses to salbutamol injected into the right coronary artery. Ten patients treated with atenolol (50-100 mg daily) were compared with 10 patients not treated with beta-blockers. The mean dose required to cause an increase in heart rate of 30 beats/min was 2.29 micrograms (log dose 0.36 +/- 0.12 micrograms [mean +/- SEM]) in the atenolol-treated patients. In the non- beta-blocker-treated patients, the dose required to cause an increase in heart rate of 30 beats/min was significantly greater, 8.91 micrograms (log dose 0.95 +/- 0.11 micrograms) (p less than 0.005). We conclude that treatment with beta 1-selective beta-blockers leads to increased cardiac responsiveness to beta 2-adrenoreceptor stimulation. This may be the underlying mechanism of the beta-blocker withdrawal syndrome and may make the heart more susceptible to the adverse effects of epinephrine in situations of stress (e.g., myocardial infarction).

This article has been cited by other articles:

				A. Jones and H. Montgomery The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies? Eur. Heart J., July 2, 2002; 23(14): 1071 - 1074. [Full Text] [PDF]

				M D Lowe, E Rowland, M J Brown, and A A Grace {beta}2 Adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium Heart, July 1, 2001; 86(1): 45 - 51. [Abstract] [Full Text] [PDF]

				O.-E. Brodde and M. C. Michel Adrenergic and Muscarinic Receptors in the Human Heart Pharmacol. Rev., December 1, 1999; 51(4): 651 - 690. [Abstract] [Full Text] [PDF]

				G. E. Newton, E. R. Azevedo, and J. D. Parker Inotropic and Sympathetic Responses to the Intracoronary Infusion of a ß2-Receptor Agonist : A Human In Vivo Study Circulation, May 11, 1999; 99(18): 2402 - 2407. [Abstract] [Full Text] [PDF]

				J G Crilley, J H Dark, and J A Hall Reversal of severe pulmonary hypertension with beta  blockade in a patient with end stage left ventricular failure Heart, December 1, 1998; 80(6): 620 - 622. [Abstract] [Full Text]

				L. Sanders, J. A. Lynham, B. Bond, F. del Monte, S. E. Harding, and A. J. Kaumann Sensitization of Human Atrial 5-HT4 Receptors by Chronic ß-Blocker Treatment Circulation, November 1, 1995; 92(9): 2526 - 2539. [Abstract] [Full Text]

				M. J Brown To (ss) block or better block? BMJ, September 16, 1995; 311(7007): 701 - 702. [Full Text]

				F. H.H. Leenen, R. A. Davies, and A. Fourney Role of Cardiac ß2-Receptors in Cardiac Responses to Exercise in Cardiac Transplant Patients Circulation, February 1, 1995; 91(3): 685 - 690. [Abstract] [Full Text]